Two New Potential Game-Changers in the Treatment of Gastroesophageal Cancer

With new studies on zolbetuximab and the discovery of Claudine 18.2 as a new biomarker, patients with limited treatment options may soon see a significant shift in their care. The KEYNOTE 811 study also brings hope to those with HER-2-positive adenocarcinoma in gastric and gastroesophageal cancer. According to KEYNOTE 811, immunotherapy paired with trastuzumab-based chemotherapy shows remarkable improvements in overall survival and progression-free survival, already gaining approval from the EMA.